Vericel’s MACI Primed for Growth

Vericel reported 4Q22 orthopedic sales of $46.4 million, +24.1% compared to 4Q21. For the full year 2022, the company's orthopedic sales totalled $132 million, +18.3% compared to the year prior.

Fourth quarter MACI results were driven by a 10% increase in biopsying surgeons and conversion rate trending upwards. Those factors generated a...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us